Viral hepatitis results in 1.4 million deaths annually. The World Health Organization (WHO)
set an ambitious target to eliminate viral hepatitis by 2030, but significant challenges remain …

Background Scientific evidence is lacking regarding the risk of patients with chronic liver
disease (CLD) for COVID-19, and how these risks are affected by age, gender and race …

Background and Aims Increasing evidence demonstrates that hepatitis C virus (HCV)
infection is associated with atherosclerosis. However, there are contrasting findings in …

Treatment with interferon (IFN) and ribavirin (RBV) significantly impairs quality of life and
other patient‐reported outcomes (PROs). Patient experience with IFN‐and RBV‐free anti …

Background. The number of deaths in hepatitis C virus (HCV)–infected persons recorded on
US death certificates has been increasing, but actual rates and causes of death in these …

The association of hepatitis C virus (HCV) infection with chronic kidney disease (CKD)
remains widely debated. Here we quantify this association by analysis of data from the …

Individuals with hepatitis C virus (HCV) infection are large users of outpatient, emergency
department, and inpatient health services in the United States. We highlight the sizable …

Abstract Background Almost 1% of Canadians are hepatitis C (HCV)-infected. The liver-
specific complications of HCV are established but the extra-hepatic comorbidity …

Background With the advent of the direct-acting antiviral agents, significant drug–drug
interaction (DDI) potential now exists for patients treated for chronic hepatitis C virus (HCV) …

Background Pain is common in patients with liver disease, difficult to treat, and poorly
understood. Aims The aim of this study was to determine factors associated with pain and …